European regulators said on Thursday they have completed their assessment of reported manufacturing violations at Ranbaxy Laboratories Ltd's facility in Toansa, India, and although deficiencies were found they pose no risk to public health.
The regulators said they were satisfied that corrective measures put in place by the company were sufficient to ensure products at the site will be in compliance with good manufacturing practices and they will reinstate the GMP certificate that was suspended in January.
Copyright: Thomson Reuters 2014
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
